What is the efficacy of Tafasitamab in the treatment of lymphomas such as DLBCL?

Tafasitamab initially showed promising results in the treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), particularly in patients who are not candidates for autologous stem cell transplantation. In the pivotal clinical trial L-MIND, Tafasitamab combined with lenalidomide (lenalidomide) demonstrated an overall response rate (ORR) of 57.5%, of which the complete response (CR) rate is about 40%, and the median progression-free survival (PFS) is 12.1 months, much higher than most traditional regimens.

The study also found that the median duration of response (DOR) of Tafasitamab combination therapy can exceed 30 months, and about half of the patients did not relapse within 2 years. For some patients who achieve complete remission, Tafasitamab maintenance therapy can be used to continue to consolidate the efficacy and significantly extend disease-free survival. This long-term remission property is extremely rare in patients who have failed conventional chemotherapy or CD20 monoclonal antibodies, highlighting its clinical advantages as an immunotherapy.

In addition to DLBCL, Tafasitamab is indicated in follicular lymphoma (FL), marginal zone Lymphoma (MZL) and other CD19positiveB cell lymphomas are also gradually being researched and applied. In 2025, the US FDA further approved its combination with lenalidomide and rituximab for the treatment of relapsed/refractory FL. Preliminary studies also showed good response rates and long response maintenance times, which means that the indications of this drug are gradually extending to low-grade lymphoma.

For elderly patients who have failed previous treatments, cannot tolerate intensive chemotherapy, or are not suitable for hematopoietic stem cell transplantation, Tafasitamab combination therapy provides a treatment option with lower toxicity and higher compliance. In addition, it has also been tried as CAR-TThe bridging treatment method of therapy is used to control disease progression, wait for cell reinfusion, and provide more patients with follow-up treatment opportunities. Overall, Tafasitamabis becoming an important supplement and breakthrough in the treatment of DLBCL and other B cell lymphomas.

Reference materials:https://www.fda.gov/drugs/